Barclays Issues Positive Forecast for Revvity (NYSE:RVTY) Stock Price

Revvity (NYSE:RVTY) had its price target raised by investment analysts at Barclays from $160.00 to $175.00 in a report released on Wednesday, Benzinga reports. The brokerage currently has an “equal weight” rating on the stock. Barclays‘s price objective points to a potential upside of 8.23% from the company’s current price.

A number of other research analysts have also recently weighed in on RVTY. Bank of America reiterated a “neutral” rating on shares of Revvity in a research note on Wednesday. KeyCorp lifted their price target on shares of Revvity from $125.00 to $165.00 and gave the stock an “overweight” rating in a report on Friday, September 4th. Royal Bank Of Canada upped their price objective on Revvity from $135.00 to $172.00 and gave the company a “sector perform” rating in a research note on Wednesday. Wall Street Zen lowered Revvity from a “buy” rating to a “hold” rating in a report on Sunday, August 16th. Finally, UBS Group initiated coverage on Revvity in a research report on Wednesday, September 9th. They issued a “neutral” rating and a $140.00 target price for the company. Six research analysts have rated the stock with a Buy rating and thirteen have given a Hold rating to the company. According to data from MarketBeat, the company currently has an average rating of “Hold” and an average target price of $128.14.

Revvity Stock Performance

NYSE:RVTY traded down $1.79 during trading on Wednesday, reaching $161.69. The company’s stock had a trading volume of 1,393,851 shares, compared to its average volume of 1,535,023. Revvity has a 12 month low of $81.22 and a 12 month high of $171.74. The firm has a market cap of $18.04 billion, a price-to-earnings ratio of 76.88, a price-to-earnings-growth ratio of 2.76 and a beta of 1.08. The firm has a 50 day moving average of $145.89 and a 200-day moving average of $112.62. The company has a debt-to-equity ratio of 0.36, a quick ratio of 1.50 and a current ratio of 1.80.

Revvity (NYSE:RVTY) last released its earnings results on Tuesday, November 3rd. The company reported $1.38 EPS for the quarter, topping analysts’ consensus estimates of $1.30 by $0.08. The company had revenue of $728.90 million for the quarter, compared to analysts’ expectations of $694.73 million. Revvity had a return on equity of 8.34% and a net margin of 8.16%. The business’s revenue for the quarter was up 4.3% compared to the same quarter last year. During the same period in the previous year, the business posted $1.18 EPS. Research analysts expect that Revvity will post 5.36 EPS for the current fiscal year.

Insider Buying and Selling at Revvity

In other Revvity news, insider Tajinder S. Vohra sold 7,330 shares of the business’s stock in a transaction that occurred on Wednesday, September 16th. The shares were sold at an average price of $140.88, for a total value of $1,032,650.40. Following the completion of the transaction, the insider owned 6,635 shares of the company’s stock, valued at $934,738.80. The trade was a 52.49% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, insider Maxwell Krakowiak sold 1,631 shares of the company’s stock in a transaction dated Monday, September 21st. The stock was sold at an average price of $144.53, for a total value of $235,728.43. Following the completion of the transaction, the insider owned 14,781 shares of the company’s stock, valued at $2,136,297.93. The trade was a 9.94% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. In the last 90 days, insiders have sold 9,045 shares of company stock worth $1,281,439. Company insiders own 0.85% of the company’s stock.

Institutional Inflows and Outflows

Several large investors have recently made changes to their positions in the business. AlphaCore Capital LLC boosted its holdings in Revvity by 135.9% in the third quarter. AlphaCore Capital LLC now owns 5,015 shares of the company’s stock valued at $767,000 after acquiring an additional 2,889 shares in the last quarter. Fulcrum Asset Management LLP bought a new position in Revvity in the 3rd quarter worth $514,000. Allspring Global Investments Holdings LLC raised its holdings in Revvity by 0.9% in the 3rd quarter. Allspring Global Investments Holdings LLC now owns 2,248,998 shares of the company’s stock worth $335,236,000 after purchasing an additional 21,124 shares in the last quarter. Heritage Family Offices LLP purchased a new stake in shares of Revvity in the 3rd quarter worth about $37,000. Finally, Westside Investment Management Inc. purchased a new stake in shares of Revvity in the 3rd quarter worth about $2,359,000. 86.65% of the stock is owned by hedge funds and other institutional investors.

Revvity News Roundup

Here are the key news stories impacting Revvity this week:

• Positive Sentiment: Revvity reported Q3 adjusted EPS of $1.38, above the roughly $1.30 consensus, and revenue of $728.9 million versus estimates of about $694.7 million. Revenue grew 4.3% year over year, with Life Sciences strength and margin expansion contributing to the beat. The company also raised its 2026 outlook. Q3 earnings beat and outlook
• Positive Sentiment: CFRA upgraded RVTY from Hold to Buy, adding a favorable analyst view after the results. CFRA upgrade
• Neutral Sentiment: Royal Bank of Canada raised its price target from $135 to $172 but retained a Sector Perform rating; the new target implied about 6.3% upside at the cited share price. RBC price target
• Neutral Sentiment: Some coverage questioned whether the stock is now expensive after its earnings-driven run. That concern may limit further gains, particularly given the high valuation noted in the provided market data. Dividend and valuation discussion

Revvity Company Profile

Revvity, Inc provides technology, products and services for the life sciences and diagnostics markets. The company supports pharmaceutical and biotechnology research, clinical laboratories and other healthcare organizations with tools used in drug discovery, biological research, disease detection and laboratory testing.

Its offerings include laboratory instruments, reagents, consumables, software and workflow solutions. Key areas include genomics, proteomics, cellular analysis, imaging, screening, automation and reproductive health, as well as newborn screening and other diagnostic applications.